# Rituximab Maintenance Therapy for Marginal Zone B-cell Lymphoma (MZL)

> **NCT01213095** · PHASE2 · COMPLETED · sponsor: **Dong-A University Hospital** · enrollment: 48 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** rituximab

## Key facts

- **NCT ID:** NCT01213095
- **Lead sponsor:** Dong-A University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2013-09
- **Final completion:** 2015-09
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2016-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01213095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01213095, "Rituximab Maintenance Therapy for Marginal Zone B-cell Lymphoma (MZL)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01213095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*